RenovoRx Raises FY2026 Sales Guidance from $3.000M-$4.000M to $3.750M-$4.250M vs $3.203M Est

Benzinga Newsdesk www.benzinga.com Positive 94.2%

Neg 0% Neu 0% Pos 94.2%

RenovoRx (NASDAQ:RNXT) raises FY2026 sales outlook from $3.000 million-$4.000 million to $3.750 million-$4.250 million vs $3.203 million estimate.